The ICU is Your Oyster: Critical Care Clinical Pearls
According to the Society for Critical Care Medicine (SCCM), more than 5 million patients are admitted to intensive care units in the United States each year. As many hospital pharmacists will encounter critically ill patients during their careers, it is essential that they be aware of relevant and unique practice recommendations related to patients in intensive care units (ICU). This CE activity provides important pearls of critical care pharmacy while providing re-education to critical care pharmacists on these topics.
Learning Objectives
Upon completion of this activity, the participant will be able to:
- Evaluate critically ill patients for appropriate stress ulcer and venous thromboembolism prophylaxis.
- Analyze the role of dexmedetomidine as a sedating agent in critically ill patients.
- Compare hypertonic saline and mannitol for lowering of intracranial pressure in patients with cerebral edema.
- Assess the utility of low molecular weight heparin anti-Xa assays for apixaban and rivaroxaban.
Presenter
Hannah Ritchie, PharmD, is a PGY2 Pharmacy Resident at Baystate Medical Center in Springfield, Massachusetts. Hannah earned her Doctor of Pharmacy degree in 2020 from the University of Rhode Island, College of Pharmacy. Hannah’s primary interest areas include critical care, emergency medicine, and academia.
Registration Fee: This module is provided free of charge.
Release Date: June 8, 2022
Expiration Date: June 8, 2023
ACPE UAN: 0026-0000-22-131-H01-P | Application
ACPE Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEU).
To receive credit, participants must complete pre and post-assessments, view the entire presentation, and evaluate the session. Participant credit will be reported to the CPE Monitor upon conclusion. Transcripts may be printed from the CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Hannah Ritchie has no relevant financial relationships with ineligible companies to disclose.
Residency Director, Frank Szczerba, has no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.